In vitro models for assessing therapeutic angiogenesis

Sanz-Nogués, Clara; O’Brien, Timothy

doi:10.1016/j.drudis.2016.05.016

Cited by 28 publications

(27 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As depicted from Figure 5, 5% and 10% FBS supported healthy micro-tissue formation with high ratio of live cells. These results were in agreement with Sanz-Nogués and O'Brien [18] where they indicated the requirement of using low FBS concentrations to understand the vascularization of endothelial cells even in 2D culture. Furthermore, Rouwkema and Khademhosseini [14] also suggested that biological cues that guides the vascularization process in tissue engineered scaffolds needs to clearly identified to understand major factors in vascularization.…”

Section: Discussionsupporting

confidence: 90%

Determination of minimum serum concentration to develop scaffold free micro-tissue

Karaman¹,

Yarali²

2017

The European Research Journal

View full text Add to dashboard Cite

Objective. Formation of three-dimensional (3D) micro-tissues without scaffolds are widely used not only to define in vivo tissue formation mechanisms but also the development of different tissue-specific drugs. However, depending on high serum and growth factor concentrations, it would be hard to identify major effective biological cues on micro-tissue formation. The aim of the study is to determine the effect of different serum concentrations on Human Umbilicial Vein Endothelial Cells (HUVECs) micro-tissue formation. Methods. Micro-tissue of HUVEC line was formed by using 3D petri dish technique with medium containing 0%, 1%, 5% and 10% fetal bovine serum (FBS). On the 7th day after micro-tissue formation, live/dead cells analysis was conducted. Micrograph taken on days 1, 3, 5 and 7th of micro-tissue formation were determined by image analysis with ImageJ. Results. Sizes of micro-tissue formed with 0% FBS on day 1 and 3 determined as 277 ± 12 µm and 279 ± 20 µm, respectively; however, especially on day 7 micro-tissue size significantly decreased to 229 ± 6 µm. When live/dead analysis results were examined, high cell viability was observed in 5% and 10% FBS concentration. Although micro-tissue like structures were observed in 0% and 1% FBS concentrations dead cell ratio considerably increased compared to 5% and 10% FBS concentration. Conclusions. It has been determined that 0% and 1% serum are appropriate for determining the efficacy of biomimetic peptides and different extracellular matrix proteins on micro-tissue formation parameters of HUVEC. High cell viability in micro-tissues was observed with 5% and 10% serum concentrations.

show abstract

Section: Discussionsupporting

confidence: 90%

Determination of minimum serum concentration to develop scaffold free micro-tissue

Karaman¹,

Yarali²

2017

The European Research Journal

View full text Add to dashboard Cite

show abstract

“…The scratch assay employed in this study mimics the endothelial cell migration during wound healing in vivo [27,28]. Here, a scratch assay was used to assess the capacity of MSC-secreted factors present in MSC-conditioned medium to stimulate endothelial cell (HUVEC) migration subsequent to creating a scratch through the HUVEC monolayer.…”

Section: Angiogenic Capacity Comparable In Mscs Isolated From Donors mentioning

confidence: 99%

“…The tubule assay employed in this study mimics the endothelial cell differentiation during wound healing in vivo [28] by assessing the capacity of MSC-secreted factors to stimulate endothelial cell tubule formation over 18 h on a Matrigel substrate. Here, HUVEC cells were combined with either αMEM (negative control), EGM (positive control), or conditioned medium from either donor cohort before being plated on Matrigel.…”

Section: Angiogenic Capacity Comparable In Mscs Isolated From Donors mentioning

confidence: 99%

Impact of Type 2 Diabetes Mellitus on Human Bone Marrow Stromal Cell Number and Phenotypic Characteristics

Cassidy

Shortiss

Murphy

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Human bone marrow-derived mesenchymal stromal cells (MSCs) have been investigated in numerous disease settings involving impaired regeneration because of the crucial role they play in tissue maintenance and repair. Considering the number of comorbidities associated with type 2 diabetes mellitus (T2DM), the hypothesis that MSCs mediate these comorbidities via a reduction in their native maintenance and repair activities is an intriguing line of inquiry. Here, it is demonstrated that the number of bone marrow-derived MSCs in people with T2DM was reduced compared to that of age-matched control (AMC) donors and that this was due to a specific decrease in the number of MSCs with osteogenic capacity. There were no differences in MSC cell surface phenotype or in MSC expansion, differentiation, or angiogenic or migratory capacity from donors living with T2DM as compared to AMCs. These findings elucidate the basic biology of MSCs and their potential as mediators of diabetic comorbidities, especially osteopathies, and provide insight into donor choice for MSC-based clinical trials. This study suggests that any role of bone marrow MSCs as a mediator of T2DM comorbidity is likely due to a reduction in the osteoprogenitor population size and not due to a permanent alteration to the MSCs’ capacity to maintain tissue homeostasis through expansion and differentiation.

show abstract

“…Angiogenesis is a complex process that is involved in disease progression and tissue repair. The multifaceted, spatiotemporal mechanisms of angiogenesis along with the relatively high cost and technical skill level associated with in vivo studies make it difficult to rapidly and efficiently evaluate the efficacy of both biomaterials and molecular therapies targeting vascular network formation [1][2][3][4][5][6][7][8][9][10][11]. In vitro models provide a less expensive, more controlled, and reproducible platform for better quantification of isolated angiogenic processes in response to biomaterial, biochemical, or biophysical stimuli [3,[11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

A combined hiPSC-derived endothelial cell and in vitro microfluidic platform for assessing biomaterial-based angiogenesis

et al. 2019

View full text Add to dashboard Cite

Human induced pluripotent stem cell (hiPSC) derived angiogenesis models present a unique opportunity for patient-specific platforms to study the complex process of angiogenesis and the endothelial cell response to biomaterial and biophysical changes in a defined microenvironment. We present a refined method for differentiating hiPSCs into a CD31+ endothelial cell population (hiPSC-ECs) using a single basal medium from pluripotency to the final stage of differentiation. This protocol produces endothelial cells that are functionally competent in assays following purification. Subsequently, an in vitro angiogenesis model was developed by encapsulating the hiPSC-ECs into a tunable, growth factor sequestering hyaluronic acid (HyA) matrix where they formed stable, capillary-like networks that responded to environmental stimuli. Perfusion of the networks was demonstrated using fluorescent beads in a microfluidic device designed to study angiogenesis. The combination of hiPSC-ECs, bioinspired hydrogel, and the microfluidic platform creates a unique testbed for rapidly assessing the performance of angiogenic biomaterials.

show abstract

In vitro models for assessing therapeutic angiogenesis

Cited by 28 publications

References 72 publications

Determination of minimum serum concentration to develop scaffold free micro-tissue

Determination of minimum serum concentration to develop scaffold free micro-tissue

Impact of Type 2 Diabetes Mellitus on Human Bone Marrow Stromal Cell Number and Phenotypic Characteristics

A combined hiPSC-derived endothelial cell and in vitro microfluidic platform for assessing biomaterial-based angiogenesis

Contact Info

Product

Resources

About